TORONTO, ONTARIO--(Marketwire - June 03, 2010) - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that an abstract describing a 210-patient Malaysian study entitled "Blood-based Seven-gene Biomarker Panel for Colorectal Cancer: Validation in Malaysia" was presented yesterday at the 2010 National Committee for Clinical Research conference, Kuala Lumpur, Malaysia, June 2 to 4.
The abstract reported on the application of the seven gene biomarker panel to 99 colorectal cancer patients and 111 controls. The seven gene biomarker panel forms the basis of the company's lead product, ColonSentry™, the world's first blood test for colorectal cancer.
Quoting directly from the abstract, "Screening is key to colorectal cancer prevention and mortality reduction, but patient compliance with faecal testing and endoscopy is low. We have previously reported our patient-friendly blood-based test for colorectal cancer current risk stratification (Marshall KW, Mohr S, El Khettabi F, Nossova N, Chao S, Bao W, et al. Blood-based biomarker panel for stratifying current risk for colorectal cancer. Internat J Cancer 2010;126:1177-86). The test utilizes a seven-gene panel of biomarkers, which was validated using blood samples collected from North American patients at average risk for colorectal cancer. In this study, we evaluate this seven-gene biomarker panel in blood samples collected from patients in Malaysia."
The abstract concluded, "Our results independently confirmed and validated the study previously conducted in North America and demonstrate the performance of the seven-gene biomarker panel to discriminate between colorectal cancer and control blood samples in Malaysia."
"It is well established that the greatest barrier to reducing mortality arising from colorectal cancer is patient compliance with screening. ColonSentry™ provides a blood-based testing option that can be easily incorporated into a routine physical examination. We believe that widespread adoption of this practice would encourage more patients to be tested and enhance the effectiveness of colonoscopy, leading to earlier detection, improved patient outcomes and reduced healthcare costs," said Gailina J. Liew, President & Chief Operating Officer of GeneNews.
GeneNews is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews launched its first commercial product, ColonSentry™, a blood-based test to assess an individual's risk for colorectal cancer, in Canada in 2008. The company's first US marketing partner, Enzo Clinical Labs, is expected to launch the ColonSentry™ test in New York and New Jersey in the second half of 2010. For more information on GeneNews and ColonSentry™, visit www.genenews.com and www.ColonSentry.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.